• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Profusa Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    12/30/25 7:31:03 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care
    Get the next $PFSA alert in real time by email
    false 0001859807 0001859807 2025-12-29 2025-12-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): December 29, 2025

     

    PROFUSA, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41177   86-3437271
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    626 Bancroft Way, Suite A

    Berkeley, CA 94710

    (Address of principal executive offices, including zip code)

     

    Registrant’s telephone number, including area code: (925) 997-6925

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   PFSA   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    Background

     

    The purpose of this report is to disclose the terms of Amendment No. 3 to that certain Securities Purchase Agreement, dated as of February 11, 2025 (as previously amended, the “Purchase Agreement”), by and among the Company, Ascent Partners Fund LLC (“Ascent”), the other purchasers from time to time party thereto (together with Ascent, the “Purchasers”) and Ascent, as collateral agent for the Purchaser parties.

     

    As previously disclosed, the Company entered into Amendment No. 1 (the “Note Amendment”) to the Notes, which modified the terms of the Notes, specifically amending Section 4(b) to revise the conversion price provisions on any conversion date to be the lower of (i) the Conversion Price on such date and (ii) ninety-five percent (95%) of the lowest daily volume weighted average price (“VWAP”) for the Company’s common stock during the ten consecutive trading days immediately preceding the applicable conversion date (the “Alternate Conversion Price”), provided that in no event shall the conversion price be less than the Floor Price of twenty percent (20%) of the closing sale price of the common stock on the principal trading market on the trading day immediately preceding the Amendment’s effective date.

     

    As previously disclosed, on December 22, 2025, the Company entered into Amendment No. 2 (the “Second Amendment”) to the Purchase Agreement. Pursuant to the Second Amendment, Section 1.1 of the Purchase Agreement was amended and restated to modify the definition of Floor Price to provide for a Floor Price of at or above 11.1 cents ($0.111) per share during the period commencing on the date of the Second Amendment and ending on, but excluding, the effective date of the reverse stock split expected to be presented to the Company’s stockholders in January 2026 for their approval, if and when such reverse stock split becomes effective (the “Modification Period”). The “Floor Price” as amended and restated effective during the Modification Period, solely with respect to an aggregate number of shares of Common Stock issued and sold as Purchased Securities not to exceed 13,650,000 shares, to be sold at or above 11.1 cents ($0.111) per share and below 14 cents ($0.14). The Second Amendment further provided that upon the earliest to occur of (x) the issuance of such aggregate number of 13,650,000 shares as Purchased Securities during the Modification Period or (y) the end of the Modification Period, the Floor Price shall thereafter mean 14 cents ($0.14), the price per share of Common Stock equal to the product obtained by multiplying (x) twenty percent (20%) by (y) the Official Closing Price on July 25, 2025, in each case as further adjusted to reflect any reduction (but excluding any increase) in the price per share of Common Stock caused by any reorganization, recapitalization, non-cash dividend, share split or other similar transaction, all as provided in this Agreement. The modified Floor Price of 11.1 cents ($0.111) per share was to apply only during the Modification Period and only up to the 13,650,000 share cap relating to shares issued and sold below 14 cents ($0.14), and the unmodified definition applies to all other times and shares.

     

    Amendment No. 3 to Securities Purchase Agreement

     

    On December 29, 2025, the Company entered into Amendment No. 3 to the Purchase Agreement (“Third Amendment”). Pursuant to Section 2.1(a)(iii) of the Third Amendment, following the Second Closing, the Purchasers will be obligated, upon a Trading Day designated by the Company and reasonably acceptable to the Collateral Agent and no later than 10 Trading Days after the Company’s notice, to purchase additional Notes in an aggregate principal amount of up to $5,555,556 for an aggregate purchase price of up to $5,000,000, subject to satisfaction of specified conditions, including (A) the outstanding principal balance of the First Tranche and Second Tranche having been reduced to zero through conversion and/or repayment, (B) the absence of any Nasdaq continued-listing deficiency notice with respect to the Company’s Common Stock, (C) the effectiveness of a Registration Statement covering all Conversion Shares issuable upon conversion of the Notes issued in the first, second, and third tranches, and (D) receipt of required Stockholder Approval. If all such conditions are satisfied other than clause (B), the initial purchaser will, at the Company’s discretion, purchase a reduced principal amount of up to $3,333,333.60 for a proportional purchase price of up to $3,000,000. The Third Amendment also modifies Section 2(b) of the Notes to amend the Mandatory Prepayment Amount for a Subsequent Offering that is an Equity Line of Credit to 33.3% of the net proceeds with respect to shares under the current registration statement on Form S-1 (File No. 333-290805), or 50.0% of the net proceeds with respect to shares issued under any registration statement on Form S-1 filed after the date of the Third Amendment, in each case to repay the obligations under the Notes.

     

    1

     

     

    In addition, the Third Amendment modified Section 1 of the Notes to provide that the “Floor Price” means $0.35 per share of the Company’s common stock as of the Third Amendment Effective Date, and that the conversion price shall at no time be less than the Floor Price.

     

    The foregoing description of the Third Amendment is a summary only, does not purport to be complete, and is qualified in its entirety by reference to the full text of the Third Amendment, a copy of which is filed herewith as Exhibit 10.1 and is incorporated herein by reference. Defined terms used in the foregoing summary, but not otherwise defined, have the respective meanings ascribed to them in the Note.

     

    Item 9.01. Financial Statements and Exhibits.

     

    Exhibit   Description
    10.1   Amendment No. 3, dated December 29, 2025, to the Securities Purchase Agreement dated February 11, 2025,  by and between Profusa, Inc. and Ascent Partners Fund LLC.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    December 30, 2025 Profusa, Inc.
         
      By: /s/ Ben Hwang
      Name:  Ben Hwang
      Title: Chief Executive Officer

     

     

    3

     

    Get the next $PFSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PFSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PFSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Profusa Adds Leading Greek Vascular Surgeon to Customer Base

    Dr. Theodosios Bisdas is a renowned vascular surgeon and Head of Clinic of Vascular Surgery at the Athens Medical Center BERKELEY, Calif, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces a collaboration with Theodosios Bisdas, M.D., Ph.D., FACS, Head of Clinic of Vascular Surgery, Athens Medical Center, Greece, and previously Associate Professor for Vascular Surgery, Universitätsklinikum Münster, Germany. Dr. Bisdas has extensive experience in innovative endovascular techniq

    1/8/26 7:30:00 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    Profusa Bolsters European Commercial Network with New French Distributor, MedSell

    MedSell commercializes Lumee™ Oxygen tissue monitoring in France, building upon distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia, to now reach approximately 200,000 annual CLI cases in the European Union Agreement complements KOL collaboration with Vascular Center at Groupe Hospitalier Paris Saint Joseph, Paris that accounts for approximately 8% of all CLTI cases in France BERKELEY, Calif, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individua

    12/31/25 7:30:00 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35

    New note provides greater repayment flexibility and less dilution with elimination of mandatory amortization payments, increased conversion floor price to $0.35, and expanded mandatory ELOC payments from 33% to 50% BERKELEY, Calif, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces the restructure of its Senior Secured Convertible Note. "As part of our balance sheet recapitalization efforts, we restructured our Senior Secured Convertible Notes for greater repayment flexibility and

    12/30/25 7:30:00 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    $PFSA
    SEC Filings

    View All

    SEC Form DEF 14A filed by Profusa Inc.

    DEF 14A - Profusa, Inc. (0001859807) (Filer)

    1/2/26 6:09:46 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    Profusa Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Profusa, Inc. (0001859807) (Filer)

    12/30/25 7:31:03 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Profusa Inc.

    424B3 - Profusa, Inc. (0001859807) (Filer)

    12/23/25 9:43:26 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    $PFSA
    Financials

    Live finance-specific insights

    View All

    Profusa Announces Third Quarter Business and Financial Highlights

    Recapitalization reduced net debt to $14 million as of October 31; achieved key milestones to deliver potential 2026 revenue target BERKELEY, Calif, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces financial results for the third quarter ended September 30, 2025, and provides business highlights. Ben Hwang, Ph.D., Profusa's Chairman and CEO, said, "It was an extremely busy four months for the team, and we are proud of our achievements in such a short period of time. In the third

    11/19/25 5:44:52 PM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    Report Highlights Growth in AI Biomarker Monitoring as Industry Giant's GPUs Power Next-Gen Platform

    MarketNewsUpdates News Commentary NEW YORK, Sept. 11, 2025 /PRNewswire/ -- The global Diagnostic Biomarker market is experiencing unprecedented growth and is projected to continue to see substantial growth in years to come. A recent report from the (NIH) National Library of Medicine discussed the AI-Assisted Biomarker, said that: "Recently, advancements in healthcare digitization and personalized treatments have led to groundbreaking developments. Utilization of AI and ML has the potential to enhance comprehension of disease onset and progression, potentially uncovering new disease subtypes, unveiling novel drug targets, advancing the field of precision medicine, propelling efforts towards d

    9/11/25 8:45:00 AM ET
    $APLD
    $NBIS
    $NVDA
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology

    $PFSA
    Leadership Updates

    Live Leadership Updates

    View All

    Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O'Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO

    Board addition served in the Trump Administration, overseeing 1,300 facilities serving more than 9 million veterans; New CFO has led finance and operations at companies including Northrop Grumman, Stanley Black & Decker, and DuPont Berkeley, Calif, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces two major leadership additions as of the close of the business combination with NorthView Acquisition Corp (NVAC).  Peter O'Rourke, former Acting U.S. Secretary of Veterans Affair

    8/19/25 8:15:00 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care